Department of Medical and Clinical Psychology, Tilburg University, 500 LE Tilburg, The Netherlands.
Department of Clinical Chemistry and Laboratory Medicine, Medisch Spectrum Twente, Medlon BV, Enschede, The Netherlands.
Br J Nutr. 2021 Jan 14;125(1):71-78. doi: 10.1017/S000711452000255X. Epub 2020 Jul 14.
The present study reports on first-trimester reference ranges of plasma mineral Se/Zn/Cu concentration in relation to free thyroxine (FT4), thyrotropin (TSH) and thyroid peroxidase antibodies (TPO-Ab), assessed at 12 weeks' gestation in 2041 pregnant women, including 544 women not taking supplements containing Se/Zn/Cu. The reference range (2·5th-97·5th percentiles) in these 544 women was 0·72-1·25 µmol/l for Se, 17·15-35·98 µmol/l for Cu and 9·57-16·41 µmol/l for Zn. These women had significantly lower mean plasma Se concentration (0·94 (sd 0·12) µmol/l) than those (n 1479) taking Se/Zn/Cu supplements (1·03 (sd 0·14) µmol/l; P < 0·001), while the mean Cu (26·25 µmol/l) and Zn (12·55 µmol/l) concentrations were almost identical in these sub-groups. Women with hypothyroxinaemia (FT4 below reference range with normal TSH) had significantly lower plasma Zn concentrations than euthyroid women. After adjusting for covariates including supplement intake, plasma Se (negatively), Zn and Cu (positively) concentrations were significantly related to logFT4; Se and Cu (but not Zn) were positively and significantly related to logTSH. Women taking additional Se/Zn/Cu supplements were 1·46 (95 % CI 1·09, 2·04) times less likely to have elevated titres of TPO-Ab at 12 weeks of gestation. We conclude that first-trimester Se reference ranges are influenced by Se-supplement intake, while Cu and Zn ranges are not. Plasma mineral Se/Zn/Cu concentrations are associated with thyroid FT4 and TSH concentrations. Se/Zn/Cu supplement intake affects TPO-Ab status. Future research should focus on the impact of trace mineral status during gestation on thyroid function.
本研究报告了 2041 名孕妇在 12 孕周时血浆矿物质硒/锌/铜浓度与游离甲状腺素 (FT4)、促甲状腺素 (TSH) 和甲状腺过氧化物酶抗体 (TPO-Ab) 的关系,其中包括 544 名未服用含硒/锌/铜补充剂的孕妇。这 544 名孕妇的参考范围(2.5 百分位至 97.5 百分位)为硒 0.72-1.25 μmol/L、铜 17.15-35.98 μmol/L 和锌 9.57-16.41 μmol/L。这些女性的平均血浆硒浓度显著低于服用硒/锌/铜补充剂的女性(0.94(sd 0.12)μmol/L;n=1479)(1.03(sd 0.14)μmol/L;P<0.001),而两组的铜(26.25 μmol/L)和锌(12.55 μmol/L)浓度几乎相同。亚临床甲状腺功能减退症(FT4 低于参考范围,TSH 正常)女性的血浆锌浓度显著低于甲状腺功能正常的女性。在校正包括补充剂摄入在内的协变量后,血浆硒(负相关)、锌和铜(正相关)浓度与 logFT4 显著相关;硒和铜(但不是锌)与 logTSH 呈显著正相关。在 12 孕周时,额外服用硒/锌/铜补充剂的女性发生 TPO-Ab 升高的几率降低 1.46 倍(95 % CI 1.09,2.04)。我们得出结论,孕早期硒参考范围受硒补充剂摄入的影响,而铜和锌范围不受影响。血浆矿物质硒/锌/铜浓度与甲状腺 FT4 和 TSH 浓度相关。硒/锌/铜补充剂的摄入影响 TPO-Ab 状态。未来的研究应集中在妊娠期间微量元素状态对甲状腺功能的影响。